Efficacy and Safety of Netakimab in Children and Adolescents with Moderate-to-Severe Plaque Psoriasis: Results of the Core Treatment Period (12 Weeks) of the Randomized Placebo-Controlled Phase III Clinical Trial BCD-085-16/PLANETA-KIDS

Netakimab is a humanized anti-interleukin-17A monoclonal antibody, it has marketing approval for treatment of adult patients with moderate-tosevere plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. This paper provides the results of the first 12-week period of phase III BCD-085-16/PLANETA-KIDS clinical study.

Objective. The aim of the BCD-085-16/PLANETA-KIDS is to evaluate netakimab efficacy and safety in pediatric patients 6+ years old with moderate-to-severe plaque psoriasis.

Methods. BCD-085-16/PLANETA-KIDS (NCT06640517) is a randomized, double-blind, placebo-controlled phase III clinical study with open-label active-comparator arm (adalimumab). A total of 155 male and female patients aged from 6 to 18 years with confirmed moderate-to-severe plaque psoriasis were randomized to receive netakimab (n = 83), placebo (n = 35), or adalimumab (n = 37). Netakimab dosage was weight adjusted: for patients weighing 50 kg or more netakimab dose was 120 mg (two injections of 60 mg/ml each), for patients weighing less than 50 kg netakimab dose was 60 mg (one injection of 60 mg/ml). Patients in the Netakimab group received netakimab subcutaneously once per week for the first three weeks (induction) and once every 4 weeks thereafter (maintenance). Patients in the Placebo group received placebo in blinded manner like netakimab. Adalimumab was administered in open-label way in doses recommended by the product’s SmPC. In this study co-primary efficacy endpoints were the proportion of patients achieving PASI75 and sPGA0/1 at week 12.

Results. Netakimab has shown superiority over placebo for both co-primary endpoints. The proportion of patients achieving PASI75 at week 12 was 89.2% in the Netakimab group and 14.3% in the Placebo group, odds ratio (OR) 59.0, 95% CI [16.5; 211.5] (p < 0.0001). The proportion of patients achieving sPGA0/1 at week 12 was 83.1% in the Netakimab group and 8.6% in the Placebo group, OR 54.9, 95% CI [14.6; 206.5] (p < 0.0001). The subgroup analysis has shown consistent netakimab superiority over placebo for both co-primary endpoints, regardless of age, body weight and psoriasis severity. Throughout the 12-week period netakimab has shown favorable safety profile comparable to that in the Placebo group.

Conclusion. The results of the 12-week period in the BCD-085-16/PLANETA-KIDS study have shown high efficacy of netakimab compared with placebo with favorable safety profile in children aged 6 years and older and adolescents with moderate-to-severe plaque psoriasis.

1. Albanesi C, Madonna S, Gisondi P, Girolomoni G. The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. Front Immunol. 2018;9:1549. doi: https://doi.org/10.3389/fimmu.2018.01549

2. Psoriaz u detei: Manual for doctors. Murashkin NN, et al.; Murashkin NN, ed. Moscow: GEOTAR-Media; 2024. 550 p. (In Russ).]

3. De Jager ME, Van de Kerkhof PC, De Jong EM, Seyger MM. Epidemiology and prescribed treatments in childhood psoriasis: a survey among medical professionals. J Dermatolog Treat. 2009;20(5):254–258. doi: https://doi.org/10.1080/09546630902911847

4. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537–1541. doi: https://doi.org/10.1001/archderm.141.12.1537

5. Napolitano M, Megna M, Balato A, et al. Systemic Treatment of Pediatric Psoriasis: A Review. Dermatol Ther (Heidelb). 2016;6(2):125–142. doi: https://doi.org/10.1007/s13555-016-0117-6

6. Paller AS, Schenfeld J, Accortt NA, Kricorian G. A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. Pediatr Dermatol. 2019;36(3):290–297. doi: https://doi.org/10.1111/pde.13772

7. Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603. doi: https://doi.org/10.1016/j.jaad.2015.07.002

8. Paller AS, Seyger MMB, Alejandro Magariños G, et al. Efficacy and safety of ixekizumab in a phase III, randomized, doubleblind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183(2):231–241. doi: https://doi.org/10.1111/bjd.19147

9. Magnolo N, Kingo K, Laquer V, et al. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2022;86(1):122–130. doi: https://doi.org/10.1016/j.jaad.2021.08.066

10. Psoriaz: Clinical guidelines. Ministry of Health of Russian Federation; 2023. 78 p. (In Russ).]

11. General characteristics of the medicinal product Efleira®. ЛП-№(005293)-(РГ-RU) dated 12/10/2025. (In Russ).] Доступно по: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=5379177f-7a27-4b0b-be0de4f7ed6d5dcd. Ссылка активна на 18.06.2026.

12. Fredriksson T, Pettersson U. Severe psoriasis — oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244. doi: https://doi.org/10.1159/000250839.

13. Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat. 2003;14(3):158–165. doi: https://doi.org/10.1080/09546630310013360

14. Agency EM. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. London: EMEA; 2004. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigationmedicinal-products-indicated-treatment-psoriasis_en.pdf. Accessed on June 18, 2026.

15. General characteristics of the medicinal product DALIBRA®. ЛП-№(004250)-(РГ-RU) dated 15/08/2025. (In Russ).] Доступно по: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=22aa0dec-2554-4b23-9523-a14eeab7e7b7. Ссылка активна на 18.06.2026.

16. Langley RG, Feldman SR, Nyirady J, et al. The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23–31. doi: https://doi.org/10.3109/09546634.2013.865009

17. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206–212. doi: https://doi.org/10.1067/s0190-9622(03)00910-1

18. Thaçi D, Daiber W, Boehncke WH, Kaufmann R. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology. 2001;203(2):153–156. doi: https://doi.org/10.1159/000051731

19. Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70–80. doi: https://doi.org/10.1016/j.jaad.2016.07.058

20. Bissonnette R, Nigen S, Bolduc C. Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis. J Cutan Med Surg. 2008;12(5):230–234. doi: https://doi.org/10.2310/7750.2008.07055

21. Salek MS, Jung S, Brincat-Ruffini LA, et al. Clinical experience and psychometric properties of the Children’s Dermatology Life Quality Index (CDLQI), 1995–2012. Br J Dermatol. 2013;169:734–759. doi: https://doi.org/10.1111/bjd.12437

22. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x

23. Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021;35(4):938–947. doi: https://doi.org/10.1111/jdv.17002

24. Firek A, Castelo-Soccio L. Pediatric psoriasis: Biologics and oral small molecule inhibitors in modern therapy. JAAD Rev. 2025;3: 51–56. doi: https://doi.org/10.1016/j.jdrv.2024.12.008

25. Information system “State Register of Medicines”. (In Russ).] Доступно по: https://grls.minzdrav.gov.ru. Ссылка активна на 18.06.2026.

26. Kubanov AA, Bakulev AL, Samtsov AV, et al. Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-to-severe plaque psoriasis. Vestnik Dermatologii i Venerologii. 2019;95(2):15–28. (In Russ). doi: https://doi.org/10.25208/0042-4609-2019-95-2-15-28]

27. Puig L, Bakulev AL, Kokhan MM, et al. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatol Ther (Heidelb). 2021;11(4):1319–1332. doi: https://doi.org/10.1007/s13555-021-00554-4

28. Bakulev AL, Samtsov AV, Sokolovskiy EV, et al. Efficacy and safety profile of 2-year netakimab treatment in patients with moderate-to-severe plaque psoriasis in terms of the randomized double-blind placebo-controlled BCD-085-7/PLANETA clinical trial. Vestnik Dermatologii i Venerologii. 2022;98(2):42–52. (In Russ). doi: https://doi.org/10.25208/vdv1306]

29. Bakulev AL, Pritulo OA, Kuntsevich ZS, et al. Efficacy and safety of netakimab therapy in patients with moderate to severe psoriasis in real clinical practice. Vestnik Dermatologii i Venerologii. 2023;99(5):84–95. (In Russ). doi: https://doi.org/10.25208/vdv14864]

30. Korotaeva TV, Mazurov VI, Lila AM, et al. Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(5):480–488. (In Russ). doi: https://doi.org/10.47360/1995-4484-2020-480-488]

31. Korotaeva TV, Mazurov VI, Lila AM, et al. Netakimab for the treatment of psoriatic arthritis: 3-year results of the phase III BCD-085-8/PATERA study. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2024;18(4):33–42. (In Russ). doi: https://doi.org/10.14412/1996-7012-2024-4-33-42]

32. Pavlysh AV, Bakulev AL. Pharmacoeconomic analysis of the netakimab use for the treatment of psoriasis vulgaris in the health care settings of the Russian Federation. Medical Technologies. Assessment and Choice. 2025;47(2):99–105. (In Russ). doi: https://doi.org/10.17116/medtech20254702199]